The $144M Federal Shift: Why the Government is Now Focused on Microplastic Removal

For years, the public health conversation around microplastics has been stuck on a single, frustrating message: try to avoid them. Swap your plastic water bottle for glass. Filter your tap water. Avoid heating food in plastic containers. The advice has been well-intentioned, but it has always carried an uncomfortable subtext: we cannot actually do anything about the plastic that is already inside you.

That narrative officially changed on April 2, 2026. In a landmark joint announcement, the U.S. Department of Health and Human Services (HHS) and the Environmental Protection Agency (EPA) unveiled the most comprehensive federal strategy ever assembled to address microplastics as a public health threat. At the center of that strategy is a $144 million program called STOMP – and its focus is not just measuring exposure. It is removing microplastics from the human body.

What is the ARPA-H STOMP Program?

The Systematic Targeting Of MicroPlastics (STOMP) program is a nationwide, $144 million federal initiative led by the Advanced Research Projects Agency for Health (ARPA-H), an agency within HHS. Its stated mission is to create the definitive toolbox for measuring, researching, and affordably removing microplastics and nanoplastics (MNPs) from the human body.

The program was announced at a press conference at EPA headquarters in Washington, D.C., where ARPA-H Director Alicia Jackson, Ph.D., framed the challenge with unusual candor: "Microplastics are in every organ we look at – in ourselves and in our children. But we don't know which ones are harmful or how to remove them. Nobody wants unknown particles accumulating in their body. The field is working in the dark. STOMP is turning on the lights."

The STOMP program is structured across two phases, each building on the last:

Why Scientists Are Now Focusing on Removal, Not Just Exposure

The shift toward removal is not arbitrary. It reflects a growing scientific consensus that has been building for several years and has now reached a tipping point.

Researchers have documented microplastics in lung tissue, arterial plaques, and brain tissue. Animal studies have established causal links between microplastic accumulation and disease. Human studies, while still evolving, show a high correlation between microplastic burden and a range of adverse health outcomes. The particles do not simply pass through the body – they accumulate, cross cellular barriers, and disrupt biological pathways in ways that are still being mapped.

The fundamental problem with a pure avoidance strategy is that it assumes the body starts from a clean baseline. It does not. Decades of plastic production and consumption mean that virtually every person alive today carries some level of microplastic accumulation. As ARPA-H Program Manager Shannon Greene, Ph.D., stated plainly: "It's physically impossible for us to completely divorce our lives from plastics. They are in everything we touch – our clothes, the materials from which we get our food and water. We need to understand how microplastics are distributed throughout the body and what harm they are causing before we can take the next leap forward to ultimately remove them and improve human health."

This is the scientific logic behind the STOMP program's two-phase structure. You cannot design effective removal interventions without first knowing precisely which particles are present, where they concentrate, and how they move through the body. Phase One builds that foundation. Phase Two deploys it. The approach draws on pharmaceutical biology and bioremediation science – fields that have long focused on removing harmful substances from biological systems – and applies them to the microplastics problem for the first time at a federal scale.

The EPA's Historic Move: Microplastics on the CCL 6

The STOMP announcement did not stand alone. On the same day, the EPA took a parallel step with significant long-term implications: for the first time in the history of the program, the agency included microplastics as a priority contaminant group in its draft Sixth Contaminant Candidate List (CCL 6).

The CCL is a critical tool under the Safe Drinking Water Act. It drives research priorities, federal funding decisions, and future regulatory action for substances not yet subject to national drinking water standards. Inclusion on the list does not immediately constitute regulation, but it sends a clear signal: the EPA now considers microplastics a priority emerging threat and is actively evaluating them for future regulatory action. EPA Administrator Lee Zeldin stated at the press conference, "For too long, Americans have vocalized concerns about plastics in their drinking water. That ends today."

Together, the STOMP program and the CCL 6 inclusion represent the most coordinated federal response to microplastics contamination in U.S. history.

How Sifts Aligns with Emerging Federal Research Priorities on Microplastics

The federal government's new $144 million focus on microplastic removal validates a principle that has guided Sifts from the start. While the broader health industry has focused on exposure reduction – and that remains important – Sifts was built on the recognition that active removal is the necessary next frontier.

Sifts Daily is formulated around clinically studied ingredients that may support the body's natural ability to bind to plastics in the gut and flush them out before they have the opportunity to circulate further through your system. This is the same directional logic that STOMP's Phase Two is now pursuing at a clinical and regulatory scale: identify the particles, target them, and remove them.

We are not claiming to replicate what a future clinical intervention may achieve. What we are saying is that the scientific rationale behind supporting your body's natural clearance pathways – particularly in the gut, where a significant portion of ingested microplastics first accumulate and begin disrupting biological pathways – is now being validated at the highest levels of federal research.

As the STOMP program works over the coming years to develop broadly available clinical tools, Sifts offers a proactive, science-aligned approach that you can incorporate into your daily routine today. We will continue to track the emerging research from ARPA-H and update our formulation as the science advances.

What This Means for You Right Now

The STOMP program will take time to produce clinical results. Phase One proposals are due by June 2026, with Proposers' Day scheduled for April 22, 2026. Phase Two– the removal component – will follow after the first 24-month phase concludes. Broadly available, clinically validated removal tools are likely years away.

Supporting gut health is particularly important – it is the primary site where ingested particles are processed and, ideally, expelled. This is precisely where Sifts Daily is designed to work: using ingredients studied in emerging clinical trials to bind to plastics in the gut and support their natural elimination.*

The federal government has now confirmed what the science has been suggesting for years: microplastic accumulation is a real and measurable health concern, and removal is the next frontier. The question is not whether to take it seriously. The question is how proactive you want to be while the clinical tools catch up.

Frequently Asked Questions About STOMP and Microplastic Removal

Sources:
HHS Press Release: ARPA-H launches groundbreaking, $144 million program to combat toxic microplastics in the human body (April 2, 2026)
ARPA-H: STOMP Program Page
EPA: EPA, HHS Announce Historic Actions to Protect Americans from Microplastics and Safeguard Drinking Water (April 2, 2026)